Abstract
Batterham et al. report that the gut peptide hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al. cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3-36.
Original language | English (US) |
---|---|
Pages (from-to) | 1 p following 165; discussion 2 p following 165 |
Journal | Nature |
Volume | 430 |
Issue number | 6996 |
DOIs |
|
State | Published - Jul 8 2004 |
Externally published | Yes |
ASJC Scopus subject areas
- General